TG Therapeutics, Inc. (NASDAQ:TGTX) Stock Holdings Increased by Victory Capital Management Inc.

Victory Capital Management Inc. raised its stake in TG Therapeutics, Inc. (NASDAQ:TGTX) by 24.7% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 32,679 shares of the biopharmaceutical company’s stock after buying an additional 6,467 shares during the quarter. Victory Capital Management Inc.’s holdings in TG Therapeutics were worth $764,000 at the end of the most recent reporting period.

Other institutional investors also recently modified their holdings of the company. Lazard Asset Management LLC acquired a new stake in TG Therapeutics during the first quarter valued at $91,000. Price T Rowe Associates Inc. MD raised its position in TG Therapeutics by 6.2% during the first quarter. Price T Rowe Associates Inc. MD now owns 85,603 shares of the biopharmaceutical company’s stock valued at $1,303,000 after acquiring an additional 5,015 shares in the last quarter. Cetera Advisors LLC acquired a new stake in TG Therapeutics in the first quarter valued at approximately $622,000. DekaBank Deutsche Girozentrale acquired a new position in shares of TG Therapeutics during the 1st quarter worth $58,000. Finally, Assenagon Asset Management S.A. acquired a new position in shares of TG Therapeutics during the 2nd quarter worth $8,698,000. Institutional investors and hedge funds own 58.58% of the company’s stock.

TG Therapeutics Stock Up 2.2 %

Shares of TGTX stock opened at $35.00 on Friday. TG Therapeutics, Inc. has a 12 month low of $12.32 and a 12 month high of $36.84. The company has a quick ratio of 3.91, a current ratio of 4.59 and a debt-to-equity ratio of 1.27. The firm has a market cap of $5.45 billion, a PE ratio of -349.97 and a beta of 2.19. The stock has a 50 day moving average of $26.19 and a 200-day moving average of $22.04.

TG Therapeutics (NASDAQ:TGTX) last released its quarterly earnings data on Monday, November 4th. The biopharmaceutical company reported $0.02 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.03 by ($0.01). TG Therapeutics had a negative net margin of 5.42% and a negative return on equity of 8.32%. The firm had revenue of $83.90 million for the quarter, compared to the consensus estimate of $81.68 million. During the same quarter in the prior year, the firm posted $0.73 earnings per share. The business’s revenue for the quarter was down 49.4% on a year-over-year basis. On average, equities analysts predict that TG Therapeutics, Inc. will post 0.17 EPS for the current year.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on TGTX. TD Cowen started coverage on shares of TG Therapeutics in a research note on Tuesday, October 29th. They issued a “buy” rating and a $50.00 price objective for the company. HC Wainwright boosted their price target on TG Therapeutics from $49.00 to $55.00 and gave the stock a “buy” rating in a research report on Tuesday, November 5th. JPMorgan Chase & Co. increased their price objective on TG Therapeutics from $30.00 to $43.00 and gave the company an “overweight” rating in a report on Monday. B. Riley boosted their target price on TG Therapeutics from $29.00 to $34.00 and gave the stock a “buy” rating in a report on Wednesday, August 7th. Finally, The Goldman Sachs Group upped their target price on TG Therapeutics from $20.00 to $22.00 and gave the stock a “neutral” rating in a research report on Tuesday, November 5th. Two investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $40.67.

Insiders Place Their Bets

In other news, Director Sagar Lonial sold 5,000 shares of the company’s stock in a transaction that occurred on Monday, November 11th. The shares were sold at an average price of $30.44, for a total transaction of $152,200.00. Following the transaction, the director now directly owns 100,195 shares in the company, valued at approximately $3,049,935.80. This represents a 4.75 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 10.50% of the company’s stock.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.